Please login to the form below

Not currently logged in
Email:
Password:

Lindsay Rocco to lead corporate communications at Dendreon

Joins from agency Rx Mosaic Health

Lindsay Rocco, DendreonDendreon has appointed Rx Mosaic Health's Lindsay Rocco to executive VP, corporate communications.

The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John Johnson.

Rocco was most recently senior VP at healthcare communications agency Rx Mosaic Health, a position she held since February 2010.

She has previous communications experience within the industry too, serving as director, public affairs at Roche, prior to her time at Rx Mosaic Health.

“Lindsay is a seasoned communicator with a deep understanding of the oncology space and a true passion for Dendreon's mission to help advanced prostate cancer patients lead longer and better lives,” said Johnson.

“Lindsay's energy and expertise in healthcare communications makes her an ideal addition to our leadership team.”

15th November 2012

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics